期刊
LANCET ONCOLOGY
卷 16, 期 3, 页码 E123-E136出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(14)70409-7
关键词
-
类别
资金
- National Institutes of Health (NCI) [2 K12 CA001727-14, 1 U10 CA098543]
- National Cancer Institute [CA 21765]
- American Lebanese Syrian Associated Charities
- Dutch Cancer Society, Amsterdam, Netherlands [UVA 2011-4938]
- 7th Framework Program of the European Union, PanCareSurfUp [257505]
- NCI/NIDDK [1R01CA113930]
- NIDDK [1R01DK072124]
- Stichting Kinderen Kankervrij, Netherlands
- Tom Voute Foundation, Amsterdam, Netherlands
Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation are at an increased risk of developing congestive heart failure. In this population, congestive heart failure is well recognised as a progressive disorder, with a variable period of asymptomatic cardiomyopathy that precedes signs and symptoms. As a result, several clinical practice guidelines have been developed independently to help with detection and treatment of asymptomatic cardiomyopathy. These guidelines differ with regards to definitions of at-risk populations, surveillance modality and frequency, and recommendations for interventions. Differences between these guidelines could hinder the effective implementation of these recommendations. We report on the results of an international collaboration to harmonise existing cardiomyopathy surveillance recommendations using an evidence-based approach that relied on standardised definitions for outcomes of interest and transparent presentation of the quality of the evidence. The resultant recommendations were graded according to the quality of the evidence and the potential benefit gained from early detection and intervention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据